GlassScriptPhysician profile
Fang Sun
NPI 1831585322
$2,193.33
in general payments reported to CMS, 2019-2025
9 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,425 · 2023: $413 · 2024: $134 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.34 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $1,568.30 | 2022-2023 | Vyvgart |
| Ucb, INC. | $269.93 | 2024-2025 | |
| Genzyme Corporation | $114.84 | 2023 | |
| Sarepta Therapeutics, INC. | $95.00 | 2023 | |
| Janssen Biotech, INC. | $84.99 | 2025 | |
| Celgene Corporation | $50.00 | 2023 | Reblozyl |
| Kedrion Biopharma, INC. | $10.27 | 2023 | Koate, Kedrab, Gammaked |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.